Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer®
نویسنده
چکیده
1. Block GA, Zeig S, Sugihara J et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 1–8 2. Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436–445 3. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–1800 4. USRDS. 2007. Annual Data Report: 2007; http://www.usrds.org/ adr.htm 5. Foley RN, Li S, Liu J et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16: 210–218
منابع مشابه
Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.
BACKGROUND Intravenous (IV) iron is commonly used for correcting iron deficiency anaemia in patients with chronic kidney disease (CKD). There remains a concern for its use in patients with asthma as it may trigger an acute exacerbation. Pre-treatment with a single dose of parenteral hydrocortisone may obviate this risk. METHOD We carried out a prospective study of known asthmatic patients wit...
متن کاملNefro - 25-3 - MIOLO.indd
The antigenicity of a number of different intravenous iron preparations was tested by reverse single radial immunodiffusion with antidextran antibodies. The tested products are low molecular weight iron dextran, ferumoxytol, iron isomaltoside 1000, sodium ferric gluconate, iron sucrose, and ferric carboxymaltose. Dextran-induced anaphylactic reactions have been clinically observed with low mole...
متن کاملAssessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA)
Intravenous iron preparations are typically classified as non-dextran-based or dextran/dextran-based complexes. The carbohydrate shell for each of these preparations is unique and is key in determining the various physicochemical properties, the metabolic pathway, and the immunogenicity of the iron-carbohydrate complex. As intravenous dextran can cause severe, antibody-mediated dextran-induced ...
متن کاملSafety issues with intravenous iron products in the management of anemia in chronic kidney disease.
Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized that is deficient in the majority of patients with advanced kidney disease, thereby predisposing these patients to anemia. The other cause of anemia is deficiency of iron. Iron deficiency anemia...
متن کاملClinical update: intravenous iron for anaemia.
For nearly half a century, parenteral iron has been considered dangerous and for use only in extreme situations and when oral iron was not tolerated. This proscription was based largely on poorly characterised and infrequent anaphylactoid reactions to the high-molecular-weight dextran preparation (Imferon) that for most of this time was the only product available. Moreover, when parenteral iron...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nephrology Dialysis Transplantation
دوره 23 شماره
صفحات -
تاریخ انتشار 2008